AI Summary & Key Takeaways
AI InsightConclusion: XEN implant surgery is a safe and effective surgery in terms of IOP reduction and reduction in topical drug use up to 2 years postoperatively.
📌 3 Key Takeaways
Özet
Purpose: The aim of this study is to evaluate the effect of XEN implant surgery on postoperative intraocular pressure (IOP) reduction and complications related with the surgery 2-year follow-up results in our clinic. Materials and Methods: A total of 11 eyes of 10 patients with primary open angle glaucoma who underwent XEN implant (Allergan, Dublin, Ireland) surgery were retrospectively analyzed. Patients who included in the study; 5 were female and 5 were male. The mean follow-up time was 29±2.1 months. IOP values were examined at the postoperative 1st day, 1st month, 6th month, 12th month and 24th month controls. Complete success criterion defi ned as IOP values between 6-21 mmHg without using topical antiglaucomatous medication while qualifi ed success criterion was using topical antiglaucomatous agents and having the same IOP values. Results: Seven eyes (63,6%) met the complete success criteria and In 10 eyes, it was seen that qualifi ed success criteria were met in the fi rst year. While 7 eyes (63.6%) achieved complete success in the second year controls; the number of eyes that meet the qualifi ed success criteria was again determined as 10 (90.9%). Intraoperative hemorrhage and postoperative hyphema were observed in two eyes. Anterior chamber lavage was applied to one of the eyes with hyphema. Conclusion: XEN implant surgery is a safe and effective surgery in terms of IOP reduction and reduction in topical drug use up to 2 years postoperatively.